Literature DB >> 3090109

Histogenesis of Kaposi's sarcoma in patients with and without acquired immune deficiency syndrome (AIDS).

R R Jones, J Spaull, C Spry, E W Jones.   

Abstract

Immunohistochemical studies were performed in thirty skin biopsies from patients with Kaposi's sarcoma, who did and did not have the acquired immune deficiency syndrome (AIDS). Tumour histogenesis was rigorously tested using a battery of endothelial cell markers, which included two new monoclonal antibodies, EN4 and PAL E. These are both specific for endothelial cells and can be visualised in appropriately fixed paraffin embedded tissue. Whereas EN4 labels all endothelial cells, PAL E is negative in endothelium of lymphatic derivation. Lectin binding with Ulex europaeus agglutinin 1 (UEA-1) and the presence of factor VIII related antigen (FVIIIRA) and laminin were also examined. In nodular lesions of Kaposi's sarcoma the spindle cell areas were positive with EN4 and UEA-1, negative with PAL E, and showed focal staining for FVIIIRA and laminin. These results confirm that the tumour is of endothelial cell origin. Six patch stage lesions showed a network of angulated spaces, lined by cells that were positive with EN4 and UEA-1, negative with PAL E and anti-FVIIIRA, and showed only weak staining for laminin. This pattern was observed in both AIDS and non-AIDS related cases and strongly favours a lymphatic derivation for the tumour. This has important implications as it suggests that lymphatic endothelium may have special characteristics that lead to neoplastic transformation in patients with retrovirus infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090109      PMCID: PMC500035          DOI: 10.1136/jcp.39.7.742

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Kaposi's sarcoma.

Authors:  F H COX; E B HELWIG
Journal:  Cancer       Date:  1959 Mar-Apr       Impact factor: 6.860

2.  Kaposi's sarcoma in recipients of renal transplants.

Authors:  A R Harwood; D Osoba; S L Hofstader; M B Goldstein; C J Cardella; M J Holecek; R Kunynetz; R A Giammarco
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

3.  The pleural reaction to injury: a histological and electron-optical study with special reference to elastic-tissue formation.

Authors:  G Williams
Journal:  J Pathol       Date:  1970-01       Impact factor: 7.996

Review 4.  Dowling oration 1976. Malignant vascular tumours.

Authors:  E W Jones
Journal:  Clin Exp Dermatol       Date:  1976-12       Impact factor: 3.470

5.  Kaposi's sarcoma and immunosuppressive therapy: an appraisal.

Authors:  R W Gange; E W Jones
Journal:  Clin Exp Dermatol       Date:  1978-06       Impact factor: 3.470

6.  Factor VIII in Kaposi's sarcoma.

Authors:  L G Guarda; E G Silva; N G Ordóñez; J L Smith
Journal:  Am J Clin Pathol       Date:  1981-08       Impact factor: 2.493

7.  Immunohistochemical identification of factor VIII-related antigen in endothelial cells of cutaneous lesions of alleged vascular nature.

Authors:  W H Burgdorf; K Mukai; J Rosai
Journal:  Am J Clin Pathol       Date:  1981-02       Impact factor: 2.493

8.  Kaposi's sarcoma: immunohistologic evidence for an endothelial origin.

Authors:  M Nadji; A R Morales; J Ziegles-Weissman; N S Penneys
Journal:  Arch Pathol Lab Med       Date:  1981-05       Impact factor: 5.534

9.  Kaposi's sarcoma after immunosuppressive therapy with prednisone.

Authors:  R A Hoshaw; R A Schwartz
Journal:  Arch Dermatol       Date:  1980-11

10.  Lymphangioma-like Kaposi's sarcoma. A report of three cases.

Authors:  R W Gange; E W Jones
Journal:  Br J Dermatol       Date:  1979-03       Impact factor: 9.302

View more
  16 in total

1.  JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections.

Authors:  D V Parums; J L Cordell; K Micklem; A R Heryet; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  Inflammatory pseudotumor of lymph nodes. Immunohistochemical evidence for its fibrohistiocytic nature.

Authors:  F Facchetti; C De Wolf Peeters; I De Wever; G Frizzera
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

3.  HIV-associated Kaposi's sarcoma: new developments in epidemiology and molecular pathology.

Authors:  W K Roth
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Aneurysmal and haemangiopericytoma-like fibrous histiocytoma.

Authors:  B W Zelger; B G Zelger; H Steiner; D Ofner
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

5.  Weibel-Palade bodies in Kaposi's sarcoma cells.

Authors:  K H Marquart
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

6.  Lymphaticovenous differentiation in Kaposi's sarcoma. Cellular phenotypes by stage.

Authors:  M Dictor; C Andersson
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

7.  Immunostaining for CD31 and CD34 in Kaposi sarcoma.

Authors:  R Russell Jones; G Orchard; B Zelger; E Wilson Jones
Journal:  J Clin Pathol       Date:  1995-11       Impact factor: 3.411

8.  Irradiation-induced penile angiosarcoma.

Authors:  R J Prescott; A R Mainwaring
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

9.  Recognition of heterogeneous lymphokine-activated killer (LAK) receptors on Kaposi's sarcoma cells, endothelial cells, and monocytes/macrophages: evidence of distinct LAK-cell antigen on Kaposi's sarcoma cells--potential for use of LAK cells for immunotherapy.

Authors:  M U Rahman; A Mazumder
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

10.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.

Authors:  M Stürzl; W K Roth; N H Brockmeyer; C Zietz; B Speiser; P H Hofschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.